$RAPT News Article - RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC | Benzinga
https://marketwirenews.com/news-releases/rapt...95264.html